Bracco Diagnostics Inc. Announces Update on Product Portfolio Strategic decisions enable Bracco to serve better the needs of healthcare providers and patients with its enhanced pipeline offering.

Blue Earth Diagnostics Names Marco Campione as CEO Blue Earth Diagnostics announces Marco Campione as CEO to lead innovation in molecular imaging and diagnostic healthcare solutions worldwide.

Bracco Receives EcoVadis Gold Medal for Sustainability Again Bracco earns EcoVadis Gold for its sustainability initiatives, reaffirming its commitment to corporate responsibility and ethical practices.

Bracco at RSNA 2024: Innovation in Imaging Discover Bracco’s participation at RSNA 2024, showcasing groundbreaking diagnostic imaging solutions and educational programs for radiologists worldwide. 

CitraClear™ Introduced by Bracco Diagnostics Discover Bracco’s launch of CitraClear™, a preprocedure hydration beverage designed with patients in mind.

New Bracco Imaging and Arrayus Technologies Partnership Bracco Imaging partners with Arrayus Technologies to advance drug delivery for pancreatic cancer using focused ultrasound and microbubble technology.

How AI Is Revolutionizing Medical Writing Explore how AI is transforming medical writing, streamlining workflows, and improving accuracy in clinical documentation for healthcare providers.

Gadopiclenol Wins JFR 2024 Innovation Award Bracco’s gadopiclenol earns the JFR 2024 Innovation Award for its breakthrough role in improving MRI imaging quality and patient safety standards.

Bracco Diagnostics Inc. Achieves 1 Million Injections with VUEWAY® (gadopiclenol) solution for injection Bracco Diagnostics Inc. is proud to announce that its most recently FDA-approved magnetic resonance imaging (MRI) agent, VUEWAY® (gadopiclenol) solution for injection, has reached over one million patient injections at over 480 customer sites.

Bracco AiMIFY™ Receives FDA Clearance Bracco announces FDA clearance for AiMIFY™ software, improving efficiency in molecular imaging interpretation and workflow.